PDE4 inhibitors have shown promise in a range of pulmonary, dermatological and neurological diseases, but have been hampered by side effects including emesis and diarrhea . Difamilast , originated by Otsuka , recently approved for the treatment of atopic dermatitis [...]
5 minute read
Jun. 7, 2023
Difamilast is a Selective, Topical PDE4B Inhibitor Avoiding GI Side Effects
difamilast
topical PDE4 inhibitor marketed in Japan PDE4B subtype-selective inhibitor; discovery not disclosed JPET, April 11, 2023 Otsuka, Tokyo, JP
Loading...
